As per the new research report by RNCOS, “US Non-Invasive Prenatal Diagnostics - Market Insight”, the market for non-invasive prenatal diagnostics in US is expanding at a rapid rate, the latest entrant in the market being Illumina. Illumina has acquired Verinata Health for US$ 350 Million. Its entry into the market is expected to drastically modify the market landscape. Even Sequenom, the current leader in the NIPD market space, is dependent on Illumina’s next generation sequencing solutions for performing the tests. Further, two more players are expected to enter the US market in the next 5 years. With the dynamically evolving market landscape, possibilities are immense, making NIPD one of the most attractive markets in the maternal diagnostics sector.